Abnormalities, Multiple - 435 Studies Found

Completed : Non-drug Study to Evaluate the Suitability of Neurocognitive Tests and Functioning Scales for the Measurement of Cognitive and Functioning Changes in Children With Down Syndrome
: Down Syndrome
: 2015-05-20
: Other: No Intervention No intervention was administered in this study
Recruiting : Investigation of the Safety of Intranasal Glulisine in Down Syndrome
: Down Syndrome
: 2015-04-08
:
  • Drug: Insulin glulisine Insuli
Completed : Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30
: Down Syndrome
: 2015-04-13
Recruiting : Whole Blood Specimen Collection From Pregnant Subjects
:
  • Down Syndrome
  • Edwards Syndrome
  • Patau Syndrome
  • : 2015-04-27
    : Other: Observational - no intervention
Recruiting : Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome
:
  • Down Syndrome
  • Polyendocrinopathies, Autoimmune
  • Respiratory
    : 2015-04-15
    : Other: Phlebotomy White blood cell analysis: Subtypes of white blood cells will be counted by flow cytom
Recruiting : Development and Clinical Application of Two New Genetic Deafness Gene Diagnostic Kit
:
  • Waardenburg Syndrome
  • Large Vestibular Aqueduct Syndrome

: 2015-04-13
: Device: gene diagnostic kit
Recruiting : SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
:
  • 22q11 Deletion Syndrome
  • DiGeorge Syndrome
  • Trisomy 21

    • : 2015-03-02
Completed : Effects of Whole-body Vibration Training on Body Composition in Adolescents With and Without Down Syndrome
: Down Syndrome
: 2015-02-20
: Device: Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.
Completed : Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome
:
  • Prader Willi Syndrome
  • Adrenal Insufficiency

: 2015-02-05
:
  • Other: Low dose (1 mcg) ACTH stimulation test

Recruiting : Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)
: Basal Cell Carcinoma in Basal Cell Nevus Syndrome
: 2015-01-21
: Drug: SUBA-Itraconazole Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
<<< Previous | Next >>>